Nixxy, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Nixxy, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $97.91M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $6.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $3.19M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $21.25M | Aug 14, 2024 |
| FY2022 | Dec 31, 2021 | $22.18M | Mar 31, 2023 |
| FY2022 | Dec 31, 2020 | $8.50M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $6.00M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $828.9K | May 8, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $466.8K | Aug 14, 2024 |
| FY2023 | Dec 31, 2022 | $7.58M | Aug 14, 2024 |
| FY2022 | Dec 31, 2021 | $7.27M | Mar 31, 2023 |
| FY2022 | Dec 31, 2020 | $2.36M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.55M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $828.9K | May 8, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.98M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($22.59M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($7.16M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($16.47M) | Aug 14, 2024 |
| FY2022 | Dec 31, 2021 | ($16.33M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2020 | ($17.04M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($11.81M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($1.40M) | May 8, 2020 |
| FY2018 | Mar 31, 2018 | ($471.8K) | Jun 29, 2018 |
| FY2018 | Mar 31, 2017 | ($442.7K) | Jun 29, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.76M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($13.02M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($7.74M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($17.85M) | Aug 14, 2024 |
| FY2022 | Dec 31, 2021 | ($16.94M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2020 | ($6.74M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($10.50M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($1.22M) | May 8, 2020 |
| FY2018 | Mar 31, 2018 | ($442.6K) | Jun 29, 2018 |
| FY2018 | Mar 31, 2017 | ($312.0K) | Jun 29, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $246.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $41.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $416.9K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.36M | Aug 14, 2024 |
| FY2022 | Dec 31, 2021 | $1.15M | Mar 31, 2023 |
| FY2011 | Feb 29, 2012 | $46.5K | Jun 12, 2012 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Mar 31, 2018 | $442.6K | Jun 29, 2018 |
| FY2018 | Mar 31, 2017 | $312.0K | Jun 29, 2018 |
| FY2017 | Mar 31, 2016 | $294.9K | Jun 30, 2017 |
| FY2016 | Mar 31, 2015 | $393.3K | Jun 29, 2016 |
| FY2015 | Mar 31, 2014 | $1.42M | Jul 14, 2015 |
| FY2014 | Mar 31, 2013 | $1.05M | Jul 15, 2014 |
| FY2012 | Mar 31, 2012 | $1.03M | Aug 14, 2013 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($4.57M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($4.10M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($947.3K) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($6.95M) | Aug 14, 2024 |
| FY2022 | Dec 31, 2021 | ($9.02M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2020 | ($2.53M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($1.39M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($755.2K) | May 8, 2020 |
| FY2018 | Mar 31, 2018 | ($357.7K) | Jun 29, 2018 |
| FY2018 | Mar 31, 2017 | ($369.1K) | Jun 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Aug 14, 2024 |
| FY2023 | Dec 31, 2022 | $74.6K | Aug 14, 2024 |
| FY2022 | Dec 31, 2021 | $0 | Mar 31, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.18M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $6.96M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $10.49M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $14.13M | Aug 14, 2024 |
| FY2022 | Dec 31, 2021 | $26.29M | Mar 31, 2023 |
| FY2022 | Dec 31, 2020 | $5.71M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $6.48M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $221.2K | May 8, 2020 |
| FY2018 | Mar 31, 2018 | $917.7K | Jun 29, 2018 |
| FY2018 | Mar 31, 2017 | $2.0K | Jun 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.21M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $4.38M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $9.56M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $9.05M | Aug 14, 2024 |
| FY2022 | Dec 31, 2021 | $10.20M | Mar 31, 2023 |
| FY2022 | Dec 31, 2020 | $16.83M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $5.77M | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $1.58M | May 8, 2020 |
| FY2018 | Mar 31, 2018 | $93.9K | Jun 29, 2018 |
| FY2018 | Mar 31, 2017 | $2.78M | Jun 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.98M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $2.58M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $930.0K | Mar 31, 2025 |
| FY2024 | Dec 31, 2022 | $5.08M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $16.09M | Aug 14, 2024 |
| FY2022 | Dec 31, 2020 | ($11.12M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2019 | $715.4K | Mar 31, 2022 |
| FY2019 | Dec 31, 2018 | ($5.00M) | May 8, 2020 |
| FY2018 | Mar 31, 2018 | ($873.1K) | Jun 29, 2018 |
| FY2018 | Mar 31, 2017 | ($2.78M) | Jun 29, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.75M | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $6.44M | Apr 15, 2026 |
| FY2023 | Sep 30, 2023 | $7.10M | Aug 14, 2024 |
| FY2024 | Dec 31, 2022 | $7.10M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $7.72M | Aug 14, 2024 |
| FY2022 | Dec 31, 2020 | $3.52M | Mar 31, 2023 |
| FY2022 | Dec 31, 2019 | $3.52M | Mar 31, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($113.80M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($99.01M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($76.42M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($69.26M) | Aug 14, 2024 |
| FY2022 | Dec 31, 2021 | ($50.86M) | Mar 31, 2023 |
| FY2022 | Dec 31, 2020 | ($34.53M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($17.49M) | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | ($5.68M) | May 8, 2020 |
| FY2018 | Mar 31, 2018 | ($6.23M) | Jun 29, 2018 |
| FY2018 | Mar 31, 2017 | ($5.76M) | Jun 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $2.58M | Mar 31, 2022 |
| FY2022 | Dec 31, 2020 | $99.9K | Mar 31, 2022 |
| FY2022 | Dec 31, 2019 | $306.3K | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $14.2K | Mar 9, 2021 |
| FY2018 | Mar 31, 2018 | $213.6K | Jun 29, 2018 |
| FY2019 | Dec 31, 2017 | $378.1K | May 8, 2020 |
| FY2018 | Mar 31, 2017 | $2.0K | Jun 29, 2018 |
| FY2018 | Mar 31, 2016 | $13.2K | Jun 29, 2018 |
| FY2017 | Mar 31, 2015 | $13.4K | Jun 30, 2017 |
| FY2016 | Mar 31, 2014 | $4.2K | Jun 29, 2016 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.20M | Apr 15, 2026 |
| FY2024 | Feb 13, 2024 | $523.4K | Mar 31, 2025 |
| FY2022 | Dec 31, 2021 | $50.4K | Mar 31, 2022 |
| FY2022 | Dec 31, 2020 | $77.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $103.8K | Mar 9, 2021 |
| FY2019 | Dec 31, 2018 | $127.8K | May 8, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Apr 15, 2026 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (5) | Mar 31, 2025 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 25.95M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 15.09M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 1.43M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 1.09M | Aug 14, 2024 |
| FY2022 | Dec 31, 2021 | 14.57M | Mar 31, 2023 |
| FY2022 | Dec 31, 2020 | 2.20M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 3.62M | Mar 9, 2021 |
| FY2018 | Mar 31, 2018 | 131.55M | Jun 29, 2018 |
| FY2018 | Mar 31, 2017 | 2.55M | Jun 29, 2018 |
| FY2017 | Mar 31, 2016 | 2.55M | Jun 30, 2017 |